Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

Table 1 Individual patient data

Patient No.	CIGB-300 (mg)	Age	Total lesion area (mm²)		Histological diagnosis		HPV status
			Initial	End	Initial	End	Initial	End
1	14	28	289.1	187.1	CIN III	CIN III	16	16
2	14	42	186.9	117	CIN III	MIC	16	16
3	14	35	165.3	126.05	CIN III	CIN III	Neg	Neg
4	14	33	128.6	69.59	CIN III	CIN III	16	16
5	14	33	17.7	13.4	MIC	CIN III	Neg	Neg
6	14	31	103.3	0	CIN III	Koilocytosis	16	Neg
7	14	43	93.2	45.8	CIN III	CIN III	16	16
8	14	40	62.3	17.1	CIN III	CIN III	16	Neg
9	70	34	64.8	19.6	CIN III	CIN III	16	Neg
10	70	52	72.8	5.1	CIN II	Koilocytosis	16	16
11	70	30	55.9	21.5	CIN II	CIN II	Neg	Neg
12	70	54	36.8	7.6	CIN II	CIN II	Neg	Neg
13	70	36	39.6	0	CIN II	CIN I	16	Neg
14	70	20	36.1	0	CIN III	Koilocytosis	Neg	16
15	70	27	73.3	38.4	CIN III	CIN III	16	Neg
16	70	27	93.6	34.1	CIN III	CIN III	N16-N18	Neg
17	245	31	219	134	CIN III	CIN III	16	16
18	245	40	80.7	5	CIN III	CIN III	16	16
19	245	33	87.8	77	CIN III	CIN III	16	Neg
20	245	26	176	8.11	CIN III	CIN III	N.D.	N.D.
21	245	40	85	0	CIN III	CIN III	18	18
22	245	21	30.2	0	CIN III	Neg	N.D.	N.D.
23	245	26	64.8	0	CIN III	Koilocytosis	N.D.	N.D.
24	490	41	247	38	CIN II	CIN III	Neg	Neg
25	490	29	319	77	CIN II	CIN III	16	Neg
26	490	31	213	38	CIN II	MIC	16	Neg
27	490	33	23	5	CIN III	CIN II	16	16
28	490	39	215	73	CIN III	CIN III	16	N.D.
29	490	46	30.3	2.1	CIN III	CIN III	N16-N18	Neg
30	490	40	249	55	CIN III	CIN III	16	16
31	490	42	144	38	CIN III	CIN III	16	16

Abbreviations: CIN II-III (cervical intraepithelial neoplasia, grade II or III), MIC (microinvasive carcinoma), Neg: Negative, N16-N18: Non-16 Non 18, ND (not determined)

ISSN: 1471-2407